Version history

{
  "content_md": "# AB\n> Auto-generated from SciDEX local knowledge graph, hypothesis, and literature context.\n\n> This page is auto-generated from SciDEX local KG, hypothesis, and paper context.\n\n## Description\n\nAB is a gene with 53 documented edges across 83 papers, showing involvement in multiple neurological and molecular pathways.\n\n## Biological Function\n\nAB has been documented to inhibit ACHE and activate AD (amyloid precursor protein) and IBA1. It mediates AUTOPHAGY and is transported by CHAT. The gene is associated with EGF and interacts with LDLR, where it also mediates LDLR expression.\n\n## Key Relationshipships\n\n- **Inhibits:** ACHE (gene)\n- **Activates:** AD (gene), IBA1 (gene)\n- **Targets:** AD (gene)\n- **Mediates:** AUTOPHAGY (pathway), LDLR (gene)\n- **Transports:** CHAT (gene)\n- **Associated with:** EGF (gene), MOG (gene)\n- **Interacts with:** LDLR (gene), ENDOTHELIAL (cell type)\n- **Enhances:** MICROGLIA (cell type)\n- **Co-discussed with:** ACHE, AD, ALZHEIMER'S DISEASE, APOE, AΒ, ENDOTHELIAL\n\n## Relevant Hypotheses\n\nEight mechanistically relevant hypotheses have been documented involving AB:\n\n- Metabolic Reprogramming to Reverse Senescence (score=1.00)\n- Closed-loop transcranial focused ultrasound with 40Hz gamma entrainment to restore hippocampal-cortical connectivity in early MCI (score=1.00, disease=Alzheimer's disease)\n- TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration (score=0.99, disease=neurodegeneration)\n- SASP Modulation Rather Than Cell Elimination (score=0.98)\n- TREM2-Dependent Microglial Senescence Transition (score=0.95, disease=neurodegeneration)\n- Closed-loop transcranial focused ultrasound targeting EC-II SST interneurons in Alzheimer's disease (score=0.95)\n- Closed-loop optogenetic targeting PV interneurons in Alzheimer's disease (score=0.94)\n- PLCG2 Allosteric Modulation for TREM2-Dependent Microglial Dysfunction (score=0.94, disease=neurodegeneration)\n\n## Disease Associations\n\n- **Alzheimer's Disease:** via co_discussed relationship\n- **Multiple Sclerosis:** via associated_with relationship\n\n## Literature References References\n\n- Microglia-Mediated Neuroinflammation: A Potential Target for the Treatment of Cardiovascular Diseases (PMID 35642214, 2022)\n- TREM2, microglia, and Alzheimer's disease (PMID 33516818, 2021)\n- TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease (PMID 28802038, 2017)\n- Phagocytes as plaque catalysts: Human macrophages generate seeding-competent Aβ42 fibrils with cross-seeding activity (PMID 41770935, 2026)\n- Berbamine hydrochloride as a brain penetrant galectin 3 inhibitor in a model of Huntington's disease (PMID 41772384, 2026)\n- TREM2 in neurodegeneration and diseases (PMID 41792456, 2026)\n- Precision Neurodegeneration: Integrating Molecular Mechanisms, Biomarkers, and Targeted Therapeutics (PMID 41833042, 2026)\n- Emerging pathological mechanisms of Alzheimer's disease pathogenesis: from neuroimmune interactions to intercellular communication (PMID 41858793, 2026)\n\n## Amyloid Beta Pathomechanism in Alzheimer's Disease\n\nAmyloid beta (Aβ) is generated by sequential proteolytic cleavage of the amyloid precursor protein (APP) by β-secretase (BACE1) and γ-secretase. The shorter Aβ40 and longer Aβ42 isoforms have distinct aggregation properties: Aβ42 is more hydrophobic, aggregates more readily into oligomers and fibrils, and is selectively enriched in amyloid plaques. The amyloid cascade hypothesis proposes that Aβ accumulation is the primary initiating event in Alzheimer's disease (AD) pathogenesis, triggering downstream tau hyperphosphorylation, neuroinflammation, and synaptic degeneration [@PMID:37834241].\n\nSoluble Aβ oligomers — rather than insoluble fibrillar plaques — are now recognized as the primary neurotoxic species. Oligomeric Aβ disrupts synaptic long-term potentiation (LTP), impairs glutamate receptor trafficking, activates complement-mediated synapse elimination, and induces mitochondrial dysfunction. Synaptic degeneration, quantified as synapse density loss, correlates more strongly with cognitive decline in AD than does plaque or tangle burden [@PMID:36513730].\n\nMicroglial responses to Aβ are complex: early microglial activation can be protective by phagocytosing Aβ, but chronic neuroinflammation driven by Aβ seeding eventually impairs microglial function and accelerates neurodegeneration through TREM2-dependent and -independent pathways. The TREM2-IBA1-MICROGLIA axis documented in the KG edges for AB reflects this interplay between Aβ deposition, microglial activation, and disease progression.\n\n## Cross-Links\n\n- [[TREM2]] — Microglial receptor modulating Aβ phagocytosis and inflammatory responses\n- [[APP]] — Amyloid precursor protein; processed to generate Aβ peptides\n- [[BACE1]] — β-secretase; rate-limiting enzyme in Aβ generation; drug target\n- [[Tau]] — Downstream pathological protein in the amyloid cascade\n- [[Alzheimer's Disease]] — Primary disease context for Aβ biology\n",
  "entity_type": "gene",
  "kg_node_id": "AB",
  "refs_json": [
    {
      "doi": "10.2147/JIR.S350109",
      "pmid": "35642214",
      "year": 2022,
      "title": "Microglia-Mediated Neuroinflammation: A Potential Target for the Treatment of Cardiovascular Diseases.",
      "journal": "J Inflamm Res"
    },
    {
      "doi": "10.1016/j.mad.2021.111438",
      "pmid": "33516818",
      "year": 2021,
      "title": "TREM2, microglia, and Alzheimer's disease.",
      "journal": "Mech Ageing Dev"
    },
    {
      "doi": "10.1016/j.cell.2017.07.023",
      "pmid": "28802038",
      "year": 2017,
      "title": "TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease.",
      "journal": "Cell"
    },
    {
      "doi": "10.1073/pnas.2516774123",
      "pmid": "41770935",
      "year": 2026,
      "title": "Phagocytes as plaque catalysts: Human macrophages generate seeding-competent Aβ42 fibrils with cross-seeding activity.",
      "journal": "Proceedings of the National Academy of Sciences of the United States of America"
    },
    {
      "doi": "10.1093/brain/awag069",
      "pmid": "41772384",
      "year": 2026,
      "title": "Berbamine hydrochloride as a brain penetrant galectin 3 inhibitor in a model of Huntington's disease.",
      "journal": "Brain : a journal of neurology"
    },
    {
      "doi": "10.1038/s41380-026-03505-7",
      "pmid": "41792456",
      "year": 2026,
      "title": "TREM2 in neurodegeneration and diseases.",
      "journal": "Molecular psychiatry"
    },
    {
      "doi": "10.2174/0118715273435428251202075956",
      "pmid": "41833042",
      "year": 2026,
      "title": "Precision Neurodegeneration: Integrating Molecular Mechanisms, Biomarkers, and Targeted Therapeutics.",
      "journal": "CNS & neurological disorders drug targets"
    },
    {
      "doi": "10.3389/fnagi.2026.1748418",
      "pmid": "41858793",
      "year": 2026,
      "title": "Emerging pathological mechanisms of Alzheimer's disease pathogenesis: from neuroimmune interactions to intercellular communication.",
      "journal": "Frontiers in aging neuroscience"
    },
    {
      "pmid": "37834241",
      "year": 2023,
      "title": "Amyloid Precursor Protein and Alzheimer's Disease.",
      "journal": "Int J Mol Sci"
    },
    {
      "pmid": "36513730",
      "year": 2023,
      "title": "Synaptic degeneration in Alzheimer disease.",
      "journal": "Nat Rev Neurosci"
    }
  ],
  "epistemic_status": "speculative",
  "word_count": 622,
  "source_repo": "scidex_generated"
}